PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer

Tobias Maurer; Kristina Schwamborn; Margret Schottelius; Hans-Jürgen Wester; Markus Schwaiger; Jürgen E Gschwend; Matthias Eiber

doi:10.1016/j.clgc.2016.05.020

PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer

Clin Genitourin Cancer. 2016 Oct;14(5):e549-e552. doi: 10.1016/j.clgc.2016.05.020. Epub 2016 May 27.

Authors

Tobias Maurer¹, Kristina Schwamborn², Margret Schottelius³, Hans-Jürgen Wester³, Markus Schwaiger⁴, Jürgen E Gschwend⁵, Matthias Eiber⁴

Affiliations

¹ Department of Urology, Technical University of Munich, Klinikum rechts der Isar, München, Germany. Electronic address: [email protected].
² Institute of Pathology, Technical University of Munich, Klinikum rechts der Isar, München, Germany.
³ Institute of Radiochemistry, Technical University of Munich, Klinikum rechts der Isar, München, Germany.
⁴ Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, München, Germany.
⁵ Department of Urology, Technical University of Munich, Klinikum rechts der Isar, München, Germany.

PMID: 27318956
DOI: 10.1016/j.clgc.2016.05.020

No abstract available

Keywords: Biochemical recurrence; Molecular targeting; Positron emission tomography; Prostate-specific membrane antigen; Radiopharmaceuticals; Salvage surgery.

Publication types

Case Reports

MeSH terms

Antigens, Surface / analysis*
Biomarkers, Tumor / analysis
Glutamate Carboxypeptidase II / analysis*
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / surgery
Neoplasm Staging / methods
Positron-Emission Tomography
Prostatic Neoplasms / diagnostic imaging
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / surgery
Surgery, Computer-Assisted / methods
Theranostic Nanomedicine / methods*

Substances

Antigens, Surface
Biomarkers, Tumor
FOLH1 protein, human
Glutamate Carboxypeptidase II